Why Us
1. Breakthrough Technology
Myoblast Transfer Therapy (MTT) repairs gene defects and replenishes cell loss, restoring organ functions. The therapy has demonstrated exceptional safety and early signs of efficacy in both heart failure and DMD patients.
2. Strong Clinical Evidence
Extensive clinical results have shown no cases of death, coma, or organ failure in MTT procedures conducted on 32 DMD patients. Additionally, MTT has demonstrated significant improvements in muscle function, myocardial perfusion, and ventricular ejection fraction in 10 heart failure patients.
3. Large Market Potential
Heart failure alone represents a $22 billion market in North America alone, with a global market estimated at $78.7 billion. MTT addresses significant unmet needs in the field, providing an attractive market opportunity.
4. Scalable Platform Technology
MTT platform has potential applications beyond heart failure and DMD, including type II diabetes, anti-aging rejuvenation, and ischemic cardiomyopathy.